Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil

Transplantation

Volumn 92, Issue 11, 2011, Pages 1244-1251

  Le Meur, Yannick ^a   Thierry, Antoine ^b   Glowacki, François ^c   Rerolle, Jean Philippe ^d   Garrigue, Valerie ^e   Ouali, Nacera ^f   Heng, Anne Elisabeth ^g   Delahousse, Michel ^h   Albano, Laeticia ⁱ   Lang, Philippe ^j   Couzi, Lionel ^d   Jaureguy, Maite ^k   Lebranchu, Yvon ^l   Mousson, Christiane ^m   Glotz, Denis ⁿ   Kessler, Michele ^o   Vrtovsnik, François ^p   Rouanet, Stephanie ^q   Tagieva, Nailya ^q   Kamar, Nassim ^r  

^a BREST UNIVERSITY HOSPITAL   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Foch Hospital ^*  (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f HÔPITAL TENON   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h FOCH HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF NICE   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k AMIENS UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF TOURS   (France)

^m DIJON UNIVERSITY HOSPITAL   (France)

ⁿ SAINT LOUIS HOSPITAL   (France)

^o UNIVERSITY HOSPITAL OF NANCY   (France)

^p BICHAT HOSPITAL   (France)

^q Roche SAS   (France)

^r TOULOUSE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Early corticosteroid withdrawal; Kidney transplantation; Mycophenolate mofetil; Therapeutic drug monitoring

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD PRESSURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GRAFT SURVIVAL; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCLINICAL ACUTE REJECTION;

ADRENAL CORTEX HORMONES; ADULT; BIOPSY; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 81855207262     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318234e134     Document Type: Article

References (31)

1. Vanrenterghem Y, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85: 209.
2. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
3. Knight RS, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
4. Pascual J, Galeano C, Royuela A, et al. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010; 90: 343.
5. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807.
6. Vitko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/ mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: Results of the Atlas study. Transplantation 2005; 80: 1734.
7. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, doubleblind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
8. Hricik DE, O'Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A metaanalysis. J Am Soc Nephrol 1993; 4: 1300.
9. Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: A metaanalysis of randomized, controlled trials. Transplantation 2004; 78: 1548.
10. Nankivell BJ, Borrows RJ, Fung DL, et al. Natural history, risk factors and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242.
11. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion. Ther Drug Monit 2001; 23: 205.
12. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
13. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306.
14. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
15. Scholten EM, Rowshani AT, Cremers S, et al. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006; 17: 2622.
16. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6: 2006.
17. Nickerson P, Jeffery J, Gough J, et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: A pilot study. J Am Soc Nephrol 1999; 10: 1801.
18. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747.
19. Choi BS, Shin MJ, Shin SJ, et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: Ten-year experience at a single center. Am J Transplant 2005; 5: 1354.
20. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
21. Kuypers DR, Le Meur Y, Cantarovich M. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010; 5: 341.
22. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145.
23. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534.
24. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043.
25. Gourishankar S, Houde I, Keown PA, et al. The CLEAR study: A 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010; 7: 1282.
26. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The Opticept Trial. Am J Transplant 2009; 9: 1607.
27. de Winter BC, Mathot RA, van Hest RM, et al. Therapeutic drug monitoring of mycophenolic acid: Does it improve patient outcome? Expert Opin Drug Metab Toxicol 2007; 3: 251.
28. Prémaud A, Le Meur Y, Debord J, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005; 27: 354.
29. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
30. Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39: 920.
31. Standards of medical care in diabetes. American Diabetes Association. Diabetes Care 2006; 29(suppl 1): S4.